These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28272498)

  • 21. Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.
    Lian J; Huang XF; Pai N; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():62-8. PubMed ID: 23994047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia.
    Rueter LE; Ballard ME; Gallagher KB; Basso AM; Curzon P; Kohlhaas KL
    Psychopharmacology (Berl); 2004 Nov; 176(3-4):312-9. PubMed ID: 15179541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used.
    Schotte A; Bonaventure P; Janssen PF; Leysen JE
    Jpn J Pharmacol; 1995 Dec; 69(4):399-412. PubMed ID: 8786644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier.
    Taccola C; Cartot-Cotton S; Valente D; Barneoud P; Aubert C; Boutet V; Gallen F; Lochus M; Nicolic S; Dodacki A; Smirnova M; Cisternino S; Declèves X; Bourasset F
    Eur J Pharm Sci; 2018 May; 117():68-79. PubMed ID: 29427702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
    Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice.
    Xu R; Hranilovic D; Fetsko LA; Bucan M; Wang Y
    Mol Psychiatry; 2002; 7(10):1075-82. PubMed ID: 12476322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine.
    Ardizzone TD; Bradley RJ; Freeman AM; Dwyer DS
    Brain Res; 2001 Dec; 923(1-2):82-90. PubMed ID: 11743975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risperidone treatment increases CB1 receptor binding in rat brain.
    Secher A; Husum H; Holst B; Egerod KL; Mellerup E
    Neuroendocrinology; 2010; 91(2):155-68. PubMed ID: 19815998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice.
    Brzozowska N; Li KM; Wang XS; Booth J; Stuart J; McGregor IS; Arnold JC
    PeerJ; 2016; 4():e2081. PubMed ID: 27257556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression.
    Boucher AA; Hunt GE; Karl T; Micheau J; McGregor IS; Arnold JC
    Neuroscience; 2007 Nov; 149(4):861-70. PubMed ID: 17905522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment.
    Doorduin J; de Vries EF; Dierckx RA; Klein HC
    Neuropharmacology; 2014 Oct; 85():548-53. PubMed ID: 24973705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction.
    Duncan GE; Moy SS; Lieberman JA; Koller BH
    Pharmacol Biochem Behav; 2006 Nov; 85(3):481-91. PubMed ID: 17097724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The presynaptic component of the serotonergic system is required for clozapine's efficacy.
    Yadav PN; Abbas AI; Farrell MS; Setola V; Sciaky N; Huang XP; Kroeze WK; Crawford LK; Piel DA; Keiser MJ; Irwin JJ; Shoichet BK; Deneris ES; Gingrich J; Beck SG; Roth BL
    Neuropsychopharmacology; 2011 Feb; 36(3):638-51. PubMed ID: 21048700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders.
    Breier A; Su TP; Malhotra AK; Elman I; Adler CM; Weisenfeld NI; Pickar D
    Neuropsychopharmacology; 1999 Apr; 20(4):340-5. PubMed ID: 10088134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone.
    Liu X; Sun H; Zhang Y; Sun Y; Wang W; Xu L; Liu W
    Toxicol Appl Pharmacol; 2021 Jul; 422():115560. PubMed ID: 33957192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.